Plain-English translation of NCT03185468 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new type of cell therapy called 4SCAR-T cells for people with advanced or metastatic bladder cancer. Researchers take your own immune cells, modify them in a lab to recognize and attack cancer cells, and then give them back to you. The study will check whether this treatment is safe and whether it helps fight the cancer.
Advanced bladder cancer is hard to treat, especially when patients have already tried standard therapies like chemotherapy and immunotherapy. This medication offers a different approach by using your body's own immune system, trained to specifically target cancer cells that other treatments may have missed.
You likely qualify if…
You likely don't qualify if…
If you enroll, doctors will collect your blood or other tissue samples to grow and modify your immune cells in a laboratory. Once the cells are ready, you will receive an infusion of the treatment back into your body. You will then have regular follow-up visits to check how well the treatment is working and to monitor for any side effects. The trial will assess both the safety of the treatment and how effective it is at controlling your cancer.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment target
~20 participants
Started
August 2025
Primary completion
December 2028
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.